Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 8Recurrence 7Neoplasm Metastasis 7Prostatic Neoplasms 6Leukemia, Myeloid, Acute 6Hematologic Neoplasms 6Lymphoma, Non-Hodgkin 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Basal Cell 5Multiple Myeloma 4Lymphoma, Follicular 4Advanced Solid Tumors 4Wilms Tumor 3Solid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neuroblastoma 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2

Interventions

Itraconazole 2roniciclib 1aprutumab ixadotin 1anetumab ravtansine 1Diet 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Medical Oncology × Itraconazole × Clear all
NCT02824042 2020-07-31

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Bayer

Phase 1 Completed
63 enrolled

Medical Oncology

NCT02457351 2016-05-23

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Bayer

Phase 1 Completed
14 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡